Gyre Therapeutics, Inc.
GYRE
NASDAQ·Healthcare·Biotechnology·Mkt cap $764.8M
$6.86
▲ +6.52%
P/E
-33.63
Mkt Cap
$764.8M
52-Wk Range
$5.44–$9.42
52-Week Range
$5.44 - $9.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 13.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established approved product (ETUARY) with existing market presence and revenue generation
- Proprietary structural derivatives (F351/Hydronidone) with improved therapeutic potential over first-generation compounds
- Broad pipeline addressing multiple fibrotic disease indications with significant unmet medical needs
- Experienced management team with deep expertise in anti-fibrotic drug development and commercialization
Bear Case
1 risk
- Very high volatility (beta 4.8). Expect 3x market swings. Position size accordingly.
Growth
Mild headwinds expected
Steady revenue growth (10% YoY)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+13.4% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying GYRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 7, 2026
Reported EPS of -$0.12 vs -$0.06 consensus (-111.8% surprise). Revenue of $29.1M vs $26.5M expected (+9.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-111.8%
Revenue trend · last 8Q
—
+3%
-19%
+6%
+20%
+33%
+2%
+9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$25.5M
$27.9M
$22.1M
$26.8M
$30.6M
$37.2M
$22.5M
$29.1M
Margins · last 8Q
Gross
92.4%
Operating
-49.4%
Profit
-40.1%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GYRE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related